Drugs · acquisition-cost intelligence
Anoro Ellipta
umeclidinium bromide and vilanterol trifenatate· ingredient vilanterol· UMECLIDINIUM BROMIDE 62.5 ug/1; VILANTEROL TRIFENATATE 25 ug/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$7.92
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 5 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other vilanterol products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Umeclidinium and Vilanterol Ellipta | $4.87 | −$3.04 |
| Breo Ellipta | $5.37 | −$2.55 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.